Insmed Shares Rise 13% Following Q3 Revenue Beat and Increased Full-Year Guidance
Insmed (INSM) shares surged approximately 13% in Thursday trading following the release of third-quarter financial results that exceeded revenue expectations. The company's strong performance was driven by its marketed therapies, leading management to raise its full-year revenue guidance. Specifically, Insmed increased the projected revenue range for Brinsupri (brensocatib) to between $1.35 billion and $1.4 billion, up from the previous estimate of $1.25 billion to $1.40 billion. The positive momentum is expected to continue as the company scales its commercial operations for its core product portfolio.
Tickers: $INSM